# Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

> **NCT03045120** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 118 (actual)

## Conditions studied

- Chronic Phase Chronic Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03045120
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-19
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-06-20
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045120, "Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03045120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*